Opus Genetics, Inc.
Phentolamine Ophthalmic Solution 0.75%
mesopic, low-contrast conditions after keratorefractive surgery
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for Phentolamine Ophthalmic Solution 0.75% in mesopic, low-contrast conditions after keratorefractive surgery are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline results expected in the first half of 2026.”